Cargando…
Combined inhibition of PARP and EZH2 for cancer treatment: Current status, opportunities, and challenges
Tumors with BRCA1/2 mutations or homologous recombination repair defects are sensitive to PARP inhibitors through the mechanism of synthetic lethality. Several PARP inhibitors are currently approved for ovarian, breast and pancreatic cancer in clinical practice. However, more than 40% of patients wi...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Frontiers Media S.A.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9574044/ https://www.ncbi.nlm.nih.gov/pubmed/36263120 http://dx.doi.org/10.3389/fphar.2022.965244 |